Sign in
Taking peopleNo phase

Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System

Key facts

Who runs it
Mitrassist Lifesciences Limited Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
5 people, planned
Started
23 Mar 2026
Expected to end
23 Oct 2028
Type of study
Interventional
Treatments tested
  • MitraFix® Transcatheter Mitral Valve System
Record updated
30 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Who can take part

  • Moderate to severe or severe (≥3+) mitral regurgitation
  • Age ≥ 18 years
  • Patients at high risk for traditional open-heart surgery, defined as: STS mortality risk for mitral valve replacement ≥ 8%; OR presence of 2 or more frailty indices; OR presence of 2 or more major organ dysfunctions that cannot be improved post-operatively; OR other comorbidities or factors making them unsuitable for surgery
  • Anatomically suitable for transcatheter MitraFix® system implantation via a transfemoral-transseptal approach as assessed by the investigator; the transfemoral-transseptal access route meets the requirements of the delivery system
  • Able to understand the study purpose, voluntarily participate, sign the informed consent form, and willing to accept relevant examinations and clinical follow-ups

Who cannot take part

  • Presence of previous implants in the mitral position (surgical bioprosthetic or mechanical valves, surgical annuloplasty rings, etc.)
  • Concomitant tricuspid valve, aortic valve, or severe great vessel disease requiring surgical or interventional treatment
  • Contraindications to anticoagulant/antiplatelet therapy that cannot be substituted or bridged
  • Participation in another clinical study of an investigational device or drug within 3 months prior to screening that may interfere with this study
  • Infective endocarditis or evidence of active infection
  • Stroke or transient ischemic attack (TIA) within 90 days
  • Severe untreated coronary artery disease or acute myocardial infarction within 90 days; or percutaneous coronary intervention (PCI)/coronary stent implantation within 90 days
  • Severe pulmonary hypertension (resting PASP > 70 mmHg, assessed as irreversible)
  • Severe allergy to iodine contrast media, nitinol, bovine-derived materials, or other device materials that remains intolerable despite premedication
  • Any other conditions deemed unsuitable for enrollment by the investigator
  • Left ventricular ejection fraction (LVEF) < 30%
  • Chronic dialysis or expected need for long-term dialysis; or severe renal impairment (e.g., eGFR < 30 mL/min/1.73m²) unable to undergo perioperative dialysis
  • Documented coagulopathy or severe hematological disorders (e.g., platelet count < 50×10\^9/L, active bleeding), or history of heparin-induced thrombocytopenia (HIT)
  • Severe mitral stenosis
  • Severe calcification of mitral leaflets and/or annulus; anatomical structures of the mitral valve apparatus (e.g., papillary muscles) unsuitable for device implantation
  • High risk of left ventricular outflow tract obstruction (LVOTO) based on pre-operative CT/TEE planning (estimated neo-LVOT < 150 mm²), which cannot be avoided by procedural optimization
  • Severe right ventricular dysfunction: Tricuspid Annular Plane Systolic Excursion (TAPSE) < 17 mm
  • Extreme frailty preventing tolerance of the procedure, or in a state of shock requiring circulatory support
  • Implantation of CRT, CRT-D, or implantable cardioverter-defibrillator (ICD) within 30 days
  • Echocardiographic evidence of any intracardiac mass, or thrombus in the left ventricle or left atrium (including left atrial appendage)
  • Contraindications to transesophageal echocardiography (TEE)
  • Life expectancy < 12 months
  • Pregnant or breastfeeding women
  • Unsuitable for the transfemoral-transseptal approach (e.g., femoral vein diameter, calcification, tortuosity, or atrial septum/left atrial anatomy not meeting delivery system requirements)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Mitral regurgitation

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery.

Read full original descriptionShow less

The main questions it aims to answer are:

Is the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life?

Participants will:

Receive the MitraFix valve through a small tube inserted into a vein in the leg.

Visit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.

The group in the trial

  • MitraFix SystemTreatment being tested

    Participants with moderate-to-severe or severe (≥3+) mitral regurgitation who are at high surgical risk will receive the MitraFix® Transcatheter Mitral Valve System.

    Treatment: MitraFix® Transcatheter Mitral Valve System

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Clinical Study to Evaluate the Safety and Clinical Feasibility of the MitraFix® Transcatheter Mitral Valve System
Criteria questions
Built from NCT07501234, who can take part
Record updated
30 March 2026